Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865662 | 0.90 | KDM4C (0.39) | HRH4KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL17865663 | 0.78 | HRH4 (0.39) | HRH4FBP1 | |
| SCHEMBL6391899 | 0.76 | KMT2A (0.41) | KMT2ANPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL9583765 | 0.73 | KMT2A (0.46) | KMT2ANPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL30684259 | 0.73 | KDM4C (0.37) | KMT2ANPC1RAB9AKDM4CMEN1 | |
| SCHEMBL17865690 | 0.70 | HRH4 (0.49) | HRH4KMT2AALDH1A1SMN1; SMN2FBP1 | |
| SCHEMBL17865638 | 0.70 | HRH4 (0.46) | HRH4KMT2AALDH1A1SMN1; SMN2FBP1 | |
| SCHEMBL31703050 | 0.70 | L3MBTL1 (0.43) | KMT2ANPC1RAB9AKDM4CMEN1 | |
| SCHEMBL15728455 | 0.70 | KDM4C (0.35) | KMT2ANPC1RAB9AKDM4CMEN1 | |
| SCHEMBL15365454 | 0.70 | KMT2A (0.36) | KMT2ANPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | HRH4 633/4885KMT2A 4108/4885NPC1 1452/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | HRH4 739/4885KMT2A 3771/4885NPC1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.